Anika Therapeutics, Inc. (ANIK) Cash Flow Statement

The negative conversion in the most recent quarter is notable precisely because 2026Q2 was hailed as the first clean profitable quarter in the ten-quarter window; the divergence implies that reported earnings are being absorbed elsewhere on the balance sheet rather than reaching the bank. Analysts should treat the profitability inflection as provisional until operating cash flow tracks net income through at least one or two additional reporting periods.

The two consecutive negative FCF quarters in 2026 interrupt what looked like a genuine recovery in late 2025, and the fact that FCF margins swung from +13.0% (2025Q4) to -21.2% (2026Q1) within a single quarter suggests the cash profile remains hostage to timing effects rather than a durable operating rhythm. For a device-biologics manufacturer whose peers like MiMedx and Halozyme post double-digit positive FCF margins, this inconsistency materially weakens the bull case on valuation.

The $13.8M draw in 2026Q2 is the largest single-quarter working capital absorption in the entire window, occurring in a quarter when revenue was reportedly growing 15.6% and gross margins had recovered to the mid-60s; this pattern may indicate receivables build or inventory investment accompanying the revenue rebound, though the specific driver warrants closer examination of the balance sheet. Sustained working capital drag at this magnitude would effectively neutralize the cash-generative potential of Anika's restored profitability.

Capex running at or below D&A suggests Anika is in a maintenance-mode investment posture, which preserves cash in the near term but may raise questions about capacity expansion or product pipeline investment if the recent revenue recovery proves durable. The elevated 2025Q1 spend (10.8% of revenue) appears to have been episodic rather than the start of a growth-capex cycle, and analysts should monitor whether capex steps up meaningfully alongside the top-line rebound.

The sustained buyback program, funded alongside $9M of net acquisition spending in 2025Q1 and Q4, appears to be drawing on existing cash reserves rather than internally generated cash flow, which may indicate management's confidence in the balance sheet but also tightens the liquidity buffer if cash burn persists. The sharp taper from $8.7M of repurchases in 2026Q1 to $853K in 2026Q2 could suggest capital discipline was reasserted once the working capital drag became apparent, though this interpretation remains uncertain without management commentary.